Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Stake Lifted by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 58.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,126,577 shares of the biopharmaceutical company's stock after purchasing an additional 1,528,600 shares during the period. Renaissance Technologies LLC owned about 1.99% of Sangamo Therapeutics worth $1,479,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of SGMO. Wasatch Advisors LP boosted its stake in shares of Sangamo Therapeutics by 62.4% during the 1st quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company's stock valued at $13,493,000 after buying an additional 7,734,400 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Sangamo Therapeutics in the 1st quarter valued at about $331,000. State Board of Administration of Florida Retirement System increased its holdings in Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 23,650 shares during the last quarter. Finally, Acadian Asset Management LLC raised its stake in Sangamo Therapeutics by 4.0% during the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company's stock valued at $3,311,000 after buying an additional 192,385 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company's stock.

Sangamo Therapeutics Stock Down 1.5 %

Shares of NASDAQ:SGMO traded down $0.01 during trading on Friday, hitting $0.78. 2,757,473 shares of the company traded hands, compared to its average volume of 3,309,290. Sangamo Therapeutics, Inc. has a one year low of $0.29 and a one year high of $1.48. The business's fifty day moving average is $0.85 and its 200-day moving average is $0.64.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.01). Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. The company had revenue of $0.36 million during the quarter, compared to the consensus estimate of $11.40 million. Analysts predict that Sangamo Therapeutics, Inc. will post -0.47 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on SGMO shares. HC Wainwright reiterated a "buy" rating and issued a $5.00 price target on shares of Sangamo Therapeutics in a report on Thursday, August 22nd. StockNews.com began coverage on shares of Sangamo Therapeutics in a research note on Sunday, July 28th. They set a "sell" rating for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, Sangamo Therapeutics presently has an average rating of "Hold" and a consensus target price of $2.67.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.